Joshua Brumm, Dyne Therapeutics CEO
Another Duchenne clinical hold gets lifted, this time at Dyne Therapeutics
Clinical holds have hampered a host of trials testing treatments for Duchenne muscular dystrophy, but one biotech is getting the go-ahead to start its study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.